Stockreport

Aduro Biotech and Novartis Present Results from Ongoing Phase 1b Study of STING Agonist ADU-S100 (MIW815) in Combination with Anti-PD-1 Monoclonal Antibody Spartalizumab (PDR001) in Patien...

ADURO BIOTECH  (ADRO) 
Last aduro biotech earnings: 3/9 04:15 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.aduro.com
PDF ADU-S100 (MIW815) + spartalizumab combination data demonstrated antitumor activity in anti-PD-1-naïve triple-negative breast cancer (TNBC) and previously immunotherapy-t [Read more]